News Archive

16 Dec. 2013

Biomay AG successfully completes interim analysis of phase IIb study with the innovative 3rd generation grass pollen allergy vaccine BM32

Biomay announced today that an interim analysis for futility has been successfully completed for an ongoing phase IIb study (clinicaltrials.gov identifier NCT01538979) with its 3rd generation grass pollen allergy vaccine BM32....[more]

19 Nov. 2013

Biomay adds new recombinant allergens to its product offering

Biomay announces today that the company is broadening its offering of recombinant allergens. Effective immediately we make the major ragweed allergen Amb a 1 as well as the new and important house dust mite allergen Der p 23...[more]

19 Sep. 2013

Biomay completes private placement and receives ERP loan

Biomay announced today that the company has completed a private placement with a volume of 3 million Euros. The new shares were subscribed by the group of existing shareholders. In Addition, the company has been awarded a...[more]

14 Sep. 2012

Biomay Extends GMP Manufacturing Authorization for Phase III and IV Biologicals

Biomay announces the successful extension of its manufacturing authorization for biologicals for all clinical phases and for market supply. The respective authorization and certificate of GMP compliance were granted recently to...[more]

28 Jun. 2012

Biomay to present at the Rodman & Renshaw 14th Annual Global Healthcare Conference

Biomay AG announced today that the company has been selected to present at the prestigious 14th Annual Global Healthcre Conference organized by the investment bank Rodman & Renshaw. The conference will take place at the...[more]

28 Jun. 2012

Innovative Grass Pollen Allergy Vaccine Shows Efficacy in Phase IIA Trial (June 16, 2012)

A novel vaccine for grass pollen allergy has shown significant improvements for patients in a Phase IIa trial. The vaccine BM32 is based on an innovative recombinant peptide carrier technology that allows for fewer injections and...[more]

3 Nov. 2011

Biomay Initiates Development of its Novel Ragweed and Japanese Cedar Allergy Vaccines – Project Granted and Awarded by ZIT

Biomay announces today that the company received 500.000 Euro funding supporting the development of its novel vaccine candidates against ragweed and Japanese cedar pollen allergy.[more]

25 Oct. 2011

Biomay announces Initiation of First Phase II Trial with its Grass Pollen Allergy Vaccine BM32

Biomay announces today that the company has initiated a first-in-patient phase II trial with its innovative recombinant grass pollen allergy vaccine BM32.[more]

1 Oct. 2011

Biomay Appoints Clinical Advisory Board

Biomay announces the appointment of world leading allergy specialists to its Clinical Advisory Board (CAB).[more]

20 Jan. 2011

Biomay Appoints Rainer Henning as Chief Executive Officer

Biomay announces the appointment of Dr. Rainer Henning as new Chief Executive Officer.[more]

Displaying 11 to 20 of 38

Biomay AG completes capital increase in the amount of €2.8 million from existing investors

Biomay announced today that the company has successfully completed a capital increase in the amount of €2.8 million with participation from most of the existing shareholders. This capital increase brings the number of outstanding shares to 20 million. The fresh capital will be employed to complete the ongoing phase IIb studies with lead product BM32, an innovative grass pollen vaccine and advance its pipeline products to full preclinical development. Rainer Henning, CEO of Biomay commented: „We are very grateful to our shareholders, which again have demonstrated their long term commitment to the company and their faith in the successful development of our breakthrough products“. About Biomay: Biomay AG is a privately held biopharmaceutical company based in Vienna, Austria. The company is committed to be a leader in the discovery and development of innovative allergy therapeutics. Besides BM32, the company has a pipeline of products for the treatment of other major allergies caused by airborne allergens. Biomay announced today that the company has successfully completed a capital increase in the amount of €2.8 million with participation from most of the existing shareholders. This capital increase brings the number of outstanding shares to 20 million. The fresh capital will be employed to complete the ongoing phase IIb studies with lead product BM32, an innovative grass pollen vaccine and advance its pipeline products to full preclinical development. Rainer Henning, CEO of Biomay commented: „We are very grateful to our shareholders, which again have demonstrated their long term commitment to the company and their faith in the successful development of our breakthrough products“. About Biomay: Biomay AG is a privately held biopharmaceutical company based in Vienna, Austria. The company is committed to be a leader in the discovery and development of innovative allergy therapeutics. Besides BM32, the company has a pipeline of products for the treatment of other major allergies caused by airborne allergens. www.biomay.com